<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02284581</url>
  </required_header>
  <id_info>
    <org_study_id>GIM14-BIOMETA</org_study_id>
    <nct_id>NCT02284581</nct_id>
  </id_info>
  <brief_title>Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments</brief_title>
  <acronym>BIO-META</acronym>
  <official_title>Evaluation of Medical Treatments (Chemotherapy, Hormonal Therapy and Biological Therapies) in Metastatic Breast Cancer Patients According to Biologic Subtype and Line of Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Consorzio Oncotech</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Consorzio Oncotech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer is the most common cancer in many countries: in Italy about 48.000 new breast
      cancers are diagnosed every year and, despite improvements in diagnosis and therapy, about
      13.000 women die every year for this disease . About 6-7% of breast cancer patients are
      metastatic at diagnosis , while the majority of patients with stage IV has a previous history
      of breast cancer that has already been treated. According to various prognostic factors
      (tumor size, lymph nodes involvement, grading, hormone receptors status, HER-2 status), in
      the worst-case scenario, more than 30% of node-negative breast cancer patients and more than
      70% of node-positive patients relapse2.

      The evolution of metastatic breast cancer has changed considerably in the last years with the
      approval of new drugs. In fact, already in 2003 Giordano et al showed that the prognosis of
      metastatic breast cancer patients was improved significantly from 1970's to 2000 with a
      median survival of 15 months in the early 1970's compared with 60 months in the last 1990's.

      This significant survival gain was obtained with introduction of new drugs as hormonal,
      chemotherapeutic and biological agents. The greater availability of drugs has led to an
      increase in number of lines of treatment receiving by metastatic breast cancer patients.
      However, there are few published data on actual duration of metastatic breast cancer
      treatments. Moreover, there is no evidence to support a real impact on survival of treatments
      beyond the second-third line.

      Recently, a retrospective analysis of about 199 metastatic breast cancer patients treated
      with chemotherapy showed that tumor subtype is associated with the duration and number of
      lines of chemotherapy (for example HER positive versus &quot;triple-negative&quot; patients) .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objectives are to evaluate the duration of metastatic breast cancer treatments
      (chemotherapy, hormonal therapy and biological therapies) according to biological subtype
      (Luminal A, Luminal B, HER2 positive, triple-negative) and to evaluate the number of lines of
      metastatic breast cancer treatments according to biological subtype (Luminal A, Luminal B,
      HER2 positive, triple-negative).

      The secondary Objectives are to evaluate overall survival according to duration and to number
      of lines of metastatic breast cancer treatments and to identify predictive factors of number
      of lines of treatment as for example age, treatment response, biological subtype, metastatic
      sites, etc and to identify possible elements of different treatment management between
      participating sites.

      The aim of this retrospective and prospective study is to identify the duration of treatments
      (chemotherapy, hormonal therapy and biological therapies) according to biological subtype and
      line of treatment in metastatic breast cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Duration and number of lines' treatment</measure>
    <time_frame>Retrospectively from 2000 up to 2014; prospectively assested up to 32 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival according duration</measure>
    <time_frame>Retrospectively from 2000 up to 2014; prospectively assested up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival according number of lines</measure>
    <time_frame>Retrospectively from 2000 up to 2014; prospectively assested up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive factors of number of lines</measure>
    <time_frame>Retrospectively from 2000 up to 2014; prospectively assested up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment management</measure>
    <time_frame>Retrospectively from 2000 up to 2014; prospectively assested up to 32 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Retrospective cohort</arm_group_label>
    <description>All consecutive metastatic breast cancers patients treated in the participating sites with a first-line therapy (chemotherapy or hormonal therapy with or without biological therapy) from Feb 2014 retrospectively back until 2000.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective cohort</arm_group_label>
    <description>All new consecutive metastatic breast cancers patients will be treated in the participating sites with a first-line therapy (chemotherapy or hormonal therapy with or without biological therapy) from March 2014 to December 2016.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Evaluation of duration of metastatic breast cancer treatments and numer of lines according to
      biological subtype (Luminal A, Luminal B, HER2 positive, triple-negative)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Italian patient with metastatic breast cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Retrospective cohort All consecutive metastatic breast cancers patients treated in the
        participating site with a first-line therapy (chemotherapy or hormonal therapy with or
        without biological therapy) from Feb 2014 retrospectively back until 2000.

        Prospective cohort All new consecutive metastatic breast cancers patients will be treated
        in the participating site with a first-line therapy (chemotherapy or hormonal therapy with
        or without biological therapy) from March 2014 to December 2016.

        Exclusion Criteria:

        Not consecutive metastatic breast cancer patients grouped for a particular biological type
        (for example: all HER2 positive patients).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Bighin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS- Azienda Ospedaliera Universitaria San Martino-IST</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudia Bighin, MD</last_name>
    <phone>0105600898</phone>
    <email>claudia.bighin@hsanmartino.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elena Abrami, MD</last_name>
    <phone>089301545</phone>
    <email>elena.abrami@cr-technology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l'Oncologia - I.R.C.C.</name>
      <address>
        <city>Candiolo</city>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Filippo Montemurro, MD</last_name>
    </contact>
    <investigator>
      <last_name>Filippo Montemurro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedale Sant'Anna</name>
      <address>
        <city>Como</city>
        <zip>22020</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Palma Pugliese, MD</last_name>
    </contact>
    <investigator>
      <last_name>Palma Pugliese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Carlo Merlano, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marco Carlo Merlano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale `F. Spaziani`</name>
      <address>
        <city>Frosinone</city>
        <zip>03100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Carlo Poma</name>
      <address>
        <city>Mantova</city>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Giovanna Cavazzini, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Giovanna Cavazzini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliero universitaria &quot;Federico II&quot;</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Grazia Arpino, MD</last_name>
    </contact>
    <investigator>
      <last_name>Grazia Arpino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per lo studio dei Tumori - Fondazione `Pascale`</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele De Laurentiis, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michele De Laurentiis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giancarlo Bisagni, MD</last_name>
    </contact>
    <investigator>
      <last_name>Giancarlo Bisagni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Regina Elena per lo studio e la cura dei tumori</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Calibita Fatebenefratelli Isola Tiberina</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fedele Scinto, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fedele Scinto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale `SS. Trinità`</name>
      <address>
        <city>Sora</city>
        <zip>03039</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Santa Maria della Misericordia di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabio Puglisi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fabio Puglisi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria ´S. Maria della Misericordia´</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabio Puglisi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fabio Puglisi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Cardoso F, Senkus-Konefka E, Fallowfield L, Costa A, Castiglione M; ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 May;21 Suppl 5:v15-9. doi: 10.1093/annonc/mdq160.</citation>
    <PMID>20555067</PMID>
  </reference>
  <reference>
    <citation>Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, Wollins DS. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012 May 10;30(14):1715-24. doi: 10.1200/JCO.2012.42.8375. Epub 2012 Apr 3. Review.</citation>
    <PMID>22493340</PMID>
  </reference>
  <reference>
    <citation>Seah DS, Luis IV, Macrae E, Sohl J, Litsas G, Winer EP, Lin NU, Burstein HJ. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Natl Compr Canc Netw. 2014 Jan;12(1):71-80.</citation>
    <PMID>24453294</PMID>
  </reference>
  <reference>
    <citation>Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011 Aug;22(8):1736-47. doi: 10.1093/annonc/mdr304. Epub 2011 Jun 27.</citation>
    <PMID>21709140</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2014</study_first_submitted>
  <study_first_submitted_qc>November 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2014</study_first_posted>
  <last_update_submitted>May 5, 2015</last_update_submitted>
  <last_update_submitted_qc>May 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MBC</keyword>
  <keyword>metastatic</keyword>
  <keyword>breast</keyword>
  <keyword>observational</keyword>
  <keyword>disease management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

